Lilly publishes positive trial data for Taltz compared to Stelara in treating psoriasis

Lilly has published positive new trial data demonstrating the efficacy of Taltz (ixekizumab), its drug for patients with moderate to severe plaque psoriasis.

The pharmaceutical firm has spent the last 24 weeks comparing the effects of Taltz to those of Stelara (ustekinumab) as part of a study entitled IXORA-S. Stelara is currently the most common biologic prescribed for patients with the skin condition.

Trial results showed that following six months of taking Taltz, 83 percent of psoriasis patients achieved a score of 90 (the best possible) on the Psoriasis Area Severity Index, compared to just 59 percent of individuals taking Stelara.

Lead researcher Kristian Reich commented: "The data of the IXORA-S study is significant, as it demonstrates both high levels of skin improvement for patients treated with Taltz, consistent with pivotal phase III trials, as well as higher response rates over Stelara."

Taltz is designed to be taken in doses of 80 milligrams every two weeks for a period of 12 weeks. After this time, 80 milligrams should be administered at four-week intervals for a further 12 weeks.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

Image: PositiveFocus via iStock